Johnson & Johnson (NYSE: JNJ) shares dipped slightly before hours today on third-quarter results that came in ahead of the consensus forecast.
The medtech giant — one of the largest medtech companies in the world — also announced plans to separate its DePuy Synthes Orthopaedics business.
Shares of JNJ fell 0.8% to $189.36 apiece in pre-market trading today. They fell more than 1.6% to $187.71 at midday.
The New Brunswick, New Jersey-based company reported profits of $5.2 billion. That equals $2.12 per share on sales of $23.99 billion for the three months ended Sept. 28, 2025.
J&J recorded a 91.2% bottom-line gain on a sales increase of 6.8%.
Adjusted to exclude one-time items, earnings per share came in at $2.80. That landed 4¢ ahead of expectations on Wall Street. Sales also topped the forecast as experts projected $23.76 billion in revenue.
Johnson & Johnson MedTech brought in $8.43 billion in revenue, marking 6.8% growth year-over-year. The company said net acquisitions and divestitures negatively impacted growth by 0.1%.
According to a news release, electrophysiology products, Abiomed and Shockwave in Cardiovascular, wound closure products in General Surgery and Surgical Vision drove growth in the MedTech business.
“Johnson & Johnson delivered another strong performance in the third quarter fueled by the depth and strength of our portfolio and significant progress across our pipeline,” said Joaquin Duato, chair and CEO, J&J. “With a sharpened focus on the six priority areas of Oncology, Immunology, Neuroscience, Cardiovascular, Surgery and Vision, Johnson & Johnson is in a new era of accelerated growth and innovation, with pioneering treatments that will continue to transform lives.”
The company increased its sales guidance for 2025, projecting between $93.5 billion and $93.9 billion in revenue. That marks a rise from previous projections for between $93.2 billion and $93.6 billion. J&J reaffirmed its full-year adjusted EPS guidance for between $10.80 and $10.90 per share.
